Abstract:Introduction: Von Hippel-Lindau (VHL) is an inherited autosomal dominant cancer syndrome causing early-onset tumors in various organs. It poses high risks of renal cell carcinoma, hemangioblastomas, pheochromocytomas, and paragangliomas among others. VHL can be clinically diagnosed based on the Danish, international, or Dutch guidelines, or through molecular diagnosis by identifying a pathogenic variant in the VHL gene. There is now an FDA-approved HIF-2 alpha inhibitor that is effective for the treatment of VHL-related manifestations, and the identification of eligible patients is paramount to receive this benefit. In addition, the screening recommendations for VHL are extensive and result in significant burden on patients. We suspect that VHL is under-diagnosed in the clinical setting, and we further hypothesize that this burden may contribute to care gaps and disparities in access to VHL-related care. Methods: This is a single-institution, retrospective study conducted at the University of Illinois Health and Hospitals System (UIH). We assessed the prevalence of patients with VHL-related tumors by examining ICD diagnosis codes from 2010 to 2023. Additionally, we analyzed the subset of these patients who underwent germ-line genetic testing. Furthermore, we examined our cohort of VHL patients more closely to explore the burden of VHL-related care. We examined the time to germ-line genetic and cascade testing from first clinical touchpoint at UIH, as well as the total number of clinical departments accessed at UIH. Demographics, clinical characteristics, germ-line genetic testing results, and information on clinical visits were also collected from those with a molecular or clinical diagnosis of VHL. Results: We found 9,875 patients with at least one VHL-associated tumor. Among them, 1,379 had two or more VHL-associated tumors, with <2% undergoing germline genetic testing. We identified 10 individuals diagnosed with VHL. Of the ten patients, 30% were black, 30% were white, and 40% self-identified as other. Age of onset for VHL-related screening ranged from 10 to 37 years. All patients diagnosed with VHL underwent germ-line genetic testing, with 60% opting for cascade testing of at-risk family members. Patient care was fragmented, with on average, each VHL patient seeking care from five different UIC clinical departments (range 1-11) and receiving care from multiple separate institutions (range 1-4). Conclusion: Our data revealed that most patients with VHL-associated tumors did not receive genetic testing, demonstrating a potential missed opportunity for early diagnosis and interventions to improve outcomes for VHL-related disease. Furthermore, our data highlights the clinical burden of VHL, and supports the potential impact of a coordinated care program for these patients. Citation Format: Neha Hippalgaonkar, Kirsten Drabek, Aseem Aseem, Tara Maga, Lara Balay, Vivian Pan, Pamela Ganschow, Karine Tawagi, Neha Awati, Natalie Reizine. The potential impact of a Von Hippel-Lindau clinical care center for patients at the University of Illinois Chicago [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4806.

In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel–Lindau Disease

Pancreatic Neuroendocrine Tumors in French VHL Mutation Carriers

The Genotype-Phenotype Association Of Von Hipple Lindau Disease Based On Mutation Locations: A Retrospective Study Of 577 Cases In A Chinese Population

Table 1 : Comparison of the age-related risks and mean diagnostic ages of the five major VHL lesions in patients with different mutation types

Genotype-phenotype Correlations in Chinese Von Hippel-Lindau Disease Patients

Identification of a VHL gene mutation in atypical Von Hippel-Lindau syndrome: genotype–phenotype correlation and gene therapy perspective

Abstract 2559: Genotype-phenotype associations in von hippel-lindau syndrome: Implications for screening

Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program

The genetic differences between types 1 and 2 in von Hippel-Lindau syndrome: comprehensive meta-analysis

Total loss of VHL gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity

EP1.03-13 Molecular Characteristics of East Asian Patients with VHL-Mutated Non-Small-Cell Lung Cancer: A Retrospective Study

Novel Genotype-Phenotype Correlations in Five Chinese Families with Von Hippel-Lindau Disease.

Higher Prevalence of Novel Mutations in VHL Gene in Chinese Von Hippel-Lindau Disease Patients.

Advancements in Understanding the Molecular Mechanisms and Clinical Implications of Von Hippel-Lindau Syndrome: A Comprehensive Review

p.N78S and p.R161Q germline mutations of the VHL gene are present in von Hippel-Lindau syndrome in two pedigrees.

Tumors in von Hippel-Lindau Syndrome: From Head to Toe-Comprehensive State-of-the-Art Review

Abstract 4806: The potential impact of a Von Hippel-Lindau clinical care center for patients at the University of Illinois Chicago

The von Hippel-Lindau tumor suppressor gene expression level has prognostic value in neuroblastoma

Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort With Von Hippel-Lindau Disease.

Pancreatic Lesions in 3 Patients with Von Hippel-Lindau Disease

Genotype-phenotype correlation in von Hippel-Lindau disease